US2012022147A1PendingUtilityA1

2, 6 xylidine derivatives for the treatment of pain

Assignee: KANDULA MAHESHPriority: Aug 17, 2011Filed: Sep 9, 2011Published: Jan 26, 2012
Est. expiryAug 17, 2031(~5 yrs left)· nominal 20-yr term from priority
Inventors:Mahesh Kandula
A61P 35/04A61P 9/00A61P 35/00A61P 27/02A61P 29/00A61P 19/00C07D 339/04A61P 17/00A61P 13/12A61K 31/385A61P 25/00
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure herein provides a composition compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition to be used for treatment of pain. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. The compound of formula 1 may also be offered as a kit.

Claims

exact text as granted — not AI-modified
1 . A compound, comprising of formula 1: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The compound of  claim 1 , further comprising:
 a pharmaceutically acceptable salt form of compound of formula 1   
     
     
         3 . A method of treating pain, comprising:
 administering the compound of formula 1 as shown below to a patient suffering from a disease   
       
         
           
           
               
               
           
         
       
     
     
         4 . The method of treating pain of  claim 3 , wherein administering is at least one of non-invasive peroral, topical, enteral, gel, syrup, lotions, healing pads, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release, patch and parenteral methods. 
     
     
         5 . The method of treatment of  claim 3 , wherein the disease is associated with at least one of chronic disease, chronic disorder, hematological disease, inflammation, orthopedic disease, cardiovascular disease, renal disease, skin disease, neurological disease, metastasis disease and ocular complications. 
     
     
         6 . A method of making the compound of formula 1, comprising:
 adding the solution of 2,6 xylidine dissolved in dichloromethane and chloroacetyl chloride for 30 minutes at 0° C. to make a mixture;   raising the temperature of the mixture and stirring it overnight for a reaction to obtain a reaction mixture;   monitoring the completion of the reaction by thin layer chromatography;   washing the reaction mixture with water followed by washing with brine solution;   separating an organic and an inorganic layer from the reaction mixture;   drying the organic layer over anhydrous Na 2 SO 4  as a solid;   evaporating the remaining liquid to get a dry solid;   recrystallizing the dried solid using a hexane; and   filtering a recrystallized dried material to yield a compound 2.   
     
     
         7 . The method of making the compound of formula 1 as in  claim 6 , further comprising:
 adding ethyl amine solution in tetrahydrofuran to dissolve the compound 2;   stirring for four hours to dissolve the compounds 2 in tetrahydrofuran;   monitoring the reaction by thin layer chromatography;   concentrating the reaction mixture under pressure;   recrystallizing the dried solid in ethyl acetate; and   filtering the recrystallized solid and drying the solid to yield a compound 3.   
     
     
         8 . The method of making the compound of formula 1 as in  claim 7 , further comprising:
 mixing N,N-dimethyl formamide, potassium carbonate and methyl chloroacetate at room temperature by continuously stifling to the compound 3;   monitoring the progress of the reaction by thin layer chromatography;   adding ethyl acetate and water to separate an organic layer and an inorganic layer;   washing the organic layer using brine solution;   drying the organic layer over Na 2 SO 4  and evaporated under reduced pressure; and   eluting a compound 5 using column chromatography.   
     
     
         9 . The method of making the compound of formula 1 as in  claim 8 , further comprising:
 mixing a lithium aluminum hydride solution, tetra hydro furan and the compound 5 for 2 hours at room temperature to obtain a reaction mixture;   quenching the reaction mixture with a saturated ammonium chloride;   extracting an organic layer using ethyl acetate; and   evaporating and drying the organic layer over an anhydrous Na 2 SO 4  to yield a compound 6.   
     
     
         10 . The method of making the compound of formula 1 as in  claim 9 , further comprising:
 stirring a mixture of a DCM, EDCI, lipoic acid and the compound 6 for 24 hours at room temperature to obtain a reaction mixture;   diluting the reaction mixture using the DCM and a brine solution;   drying and evaporating the reaction mixture over Na 2 SO 4 ; and   purifying the dried reaction mixture using column chromatography to obtain a compound of formula 1 as a pale yellow semi-solid.   
     
     
         11 . (canceled)

Join the waitlist — get patent alerts

Track US2012022147A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.